News Quantified

ACST – acasti pharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]

Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.

Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.

-3.3%

BEAT

7.0%

BEAT

-4.9%

MISS

Form 8-K Grace Therapeutics, Inc. For: Oct 24

Form 8-K Acasti Pharma Inc. For: Oct 25

Form EFFECT Acasti Pharma Inc.

Form EFFECT Acasti Pharma Inc.

Form S-8 Acasti Pharma Inc.

Top News Gainers

12/25 Acasti Pharma Inc (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $8.00 price target on the stock. 20.6%

1/13 This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled [Investor's Business Daily] 19.5%

7/18 Form EFFECT Acasti Pharma Inc. 14.5%

8/20 Acasti Pharma: Another Fish Oil Derived Product Nearing The Market [Seeking Alpha] 10.6%

9/4 Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th 10.6%

11/4 Form 6-K Acasti Pharma Inc. For: Nov 04 9.4%

6/19 Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call 9.2%

6/26 Acasti Pharma Inc (NASDAQ: ACST) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 7.1%

8/7 Form F-3 Acasti Pharma Inc. 7.0%

8/14 Form 6-K Acasti Pharma Inc. For: Aug 14 6.2%

Top News Decliners

1/13 Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre -65.1%

2/10 Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre -28.5%

12/22 Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. (ACST) [Yahoo! Finance News] -25.6%

6/4 Form 6-K Acasti Pharma Inc. For: Jun 04 -17.8%

4/20 Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada -13.4%

8/15 Acasti Pharma Inc (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. -12.6%

1/19 Does Acasti Stock Have a Future? [Yahoo! Finance News] -12.2%

11/19 Amarin slips 3% on bearish coverage [Seeking Alpha] -11.5%

4/1 Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June [Canadian Business Journal (Canada)] -11.1%

9/30 Form 6-K Acasti Pharma Inc. For: Sep 30 -10.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day